BR112021012569A2 - Anticorpo biespecífico de ligação ao tfr - Google Patents

Anticorpo biespecífico de ligação ao tfr Download PDF

Info

Publication number
BR112021012569A2
BR112021012569A2 BR112021012569-8A BR112021012569A BR112021012569A2 BR 112021012569 A2 BR112021012569 A2 BR 112021012569A2 BR 112021012569 A BR112021012569 A BR 112021012569A BR 112021012569 A2 BR112021012569 A2 BR 112021012569A2
Authority
BR
Brazil
Prior art keywords
amino acid
seq
acid sequence
antibody
bispecific antibody
Prior art date
Application number
BR112021012569-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Keisuke MITAMURA
Ryosuke Nakano
Masayuki Kai
Nobuaki Takahashi
Original Assignee
Kyowa Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co., Ltd. filed Critical Kyowa Kirin Co., Ltd.
Publication of BR112021012569A2 publication Critical patent/BR112021012569A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
BR112021012569-8A 2018-12-28 2019-12-27 Anticorpo biespecífico de ligação ao tfr BR112021012569A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-248334 2018-12-28
JP2018248334 2018-12-28
PCT/JP2019/051594 WO2020138487A1 (ja) 2018-12-28 2019-12-27 ＴｆＲに結合するバイスペシフィック抗体

Publications (1)

Publication Number Publication Date
BR112021012569A2 true BR112021012569A2 (pt) 2021-09-14

Family

ID=71125764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021012569-8A BR112021012569A2 (pt) 2018-12-28 2019-12-27 Anticorpo biespecífico de ligação ao tfr

Country Status (13)

Country Link
US (2) US12258413B2 (https=)
EP (1) EP3903816A4 (https=)
JP (2) JP7506607B2 (https=)
KR (1) KR20210108961A (https=)
CN (1) CN113226371B (https=)
AU (1) AU2019413278B2 (https=)
BR (1) BR112021012569A2 (https=)
CA (1) CA3125316A1 (https=)
MX (1) MX2021007797A (https=)
MY (1) MY210422A (https=)
SG (1) SG11202106990PA (https=)
TW (2) TWI907249B (https=)
WO (1) WO2020138487A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
KR20250162888A (ko) * 2023-03-24 2025-11-19 바이오악틱 에이비 인간 트랜스페린 수용체 htfr1의 프로테아제-유사 도메인에 결합하는 이중특이적 항체
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US570561A (en) 1896-11-03 S peters co
US2808035A (en) 1953-04-23 1957-10-01 Riley Stoker Corp Burning wet materials
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2564268B2 (ja) 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JP3131322B2 (ja) 1991-12-17 2001-01-31 協和醗酵工業株式会社 新規α２→３シアリルトランスフェラーゼ
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
JP3756946B2 (ja) 1993-03-29 2006-03-22 協和醗酵工業株式会社 α１，３−フコシルトランスフェラーゼ
US5705614A (en) 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
DK2990420T3 (en) * 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7262278B2 (en) 2001-10-15 2007-08-28 Kirin Beer Kabushiki Kaisha Anti-HLA-DR antibody
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5522405B2 (ja) 2008-04-25 2014-06-18 協和発酵キリン株式会社 安定な多価抗体
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
KR20120024763A (ko) * 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
ES2697535T3 (es) 2009-06-11 2019-01-24 Inter Univ Research Institute Corporation Research Organization Of Information And Systems Procedimiento para la producción de proteína
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
EP2699603B1 (en) 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
CA2835603A1 (en) 2011-05-09 2012-11-15 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
EP3594240B1 (en) 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
US9388243B2 (en) 2013-05-29 2016-07-12 Samsung Electronics Co., Ltd. Method of target membrane protein depletion
DK3078744T3 (da) * 2013-12-04 2020-09-28 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
SG11201608253XA (en) 2014-04-04 2016-10-28 Kyowa Hakko Kirin Co Ltd Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity
WO2016081640A1 (en) * 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
US10508151B2 (en) * 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
JPWO2016111344A1 (ja) * 2015-01-08 2017-10-26 協和発酵キリン株式会社 Ｔｒａｉｌｒ２とｐｓｍａに結合するバイスペシフィック抗体
HUE057952T2 (hu) * 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
KR20180030030A (ko) * 2015-07-15 2018-03-21 교와 핫꼬 기린 가부시키가이샤 인간 crth2에 특이적으로 결합하는 항체
CA3023667A1 (en) * 2016-05-09 2017-11-16 Annexon, Inc. Compositions and methods for treating spinal muscular atrophy
KR102156626B1 (ko) 2018-07-16 2020-09-17 주식회사 셀바스에이아이 운동 처방 정보를 제공하는 서버 및 컴퓨터 프로그램

Also Published As

Publication number Publication date
CA3125316A1 (en) 2020-07-02
SG11202106990PA (en) 2021-07-29
KR20210108961A (ko) 2021-09-03
US20250250352A1 (en) 2025-08-07
US12258413B2 (en) 2025-03-25
EP3903816A4 (en) 2022-09-07
MX2021007797A (es) 2021-10-26
WO2020138487A1 (ja) 2020-07-02
MY210422A (en) 2025-09-22
CN113226371B (zh) 2025-05-30
US20220017635A1 (en) 2022-01-20
JP7506607B2 (ja) 2024-06-26
AU2019413278A1 (en) 2021-07-15
NZ777568A (en) 2025-05-02
JPWO2020138487A1 (ja) 2021-11-11
EP3903816A1 (en) 2021-11-03
TWI907249B (zh) 2025-12-01
CN113226371A (zh) 2021-08-06
TW202039581A (zh) 2020-11-01
AU2019413278B2 (en) 2026-04-09
TWI873112B (zh) 2025-02-21
JP2024119984A (ja) 2024-09-03
TW202517296A (zh) 2025-05-01

Similar Documents

Publication Publication Date Title
US20240059788A1 (en) BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAM
US9695237B2 (en) Anti-FOLR1 antibody
US20220259328A1 (en) Bispecific antibody binding to cd40 and fap
US20250250352A1 (en) BISPECIFIC ANTIBODY BINDING TO TfR
US20180016346A1 (en) Bispecific antibody binding to trailr2 and psma
US12466891B2 (en) Bispecific antibody binding to CD40 and GPC3
RU2810756C2 (ru) Биспецифические антитела, связывающиеся с tfr
HK40062464A (en) Bispecific antibody binding to tfr
WO2021261597A1 (ja) ＧＰＣ３とＴｆＲに結合するバイスペシフィック抗体
HK40038050A (en) Bispecific antibody which binds to cd40 and epcam